Siqueira-Neto J, Lane T, Bernatchez J, Calvet Alvarez C, Barbosa da Silva E, Giardini M
ACS Omega. 2024; 9(35):37288-37298.
PMID: 39246496
PMC: 11375811.
DOI: 10.1021/acsomega.4c05060.
Rahman S, Weng T, Qadeer A, Nawaz S, Ullah H, Chen C
Front Immunol. 2024; 15:1339470.
PMID: 38633251
PMC: 11022163.
DOI: 10.3389/fimmu.2024.1339470.
Akafity G, Kumi N, Ashong J
J Intensive Med. 2024; 4(1):3-15.
PMID: 38263976
PMC: 10800773.
DOI: 10.1016/j.jointm.2023.09.002.
Chu W, Dorlo T
J Antimicrob Chemother. 2023; 78(10):2406-2418.
PMID: 37638690
PMC: 10545508.
DOI: 10.1093/jac/dkad260.
Pandey S, Anand U, Siddiqui W, Tripathi R
Adv Med. 2023; 2023:5060665.
PMID: 36960081
PMC: 10030226.
DOI: 10.1155/2023/5060665.
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Pryce J, Taylor M, Fox T, Hine P
Cochrane Database Syst Rev. 2022; 6:CD006404.
PMID: 35726133
PMC: 9209011.
DOI: 10.1002/14651858.CD006404.pub4.
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
Ezquerra-Aznarez J, Almeida Da Silva P, Ainsa J
Microorganisms. 2021; 9(11).
PMID: 34835459
PMC: 8622410.
DOI: 10.3390/microorganisms9112335.
Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice.
Wang W, Yao J, Chen Z, Sun Y, Shi Y, Wei Y
Br J Pharmacol. 2020; 177(24):5569-5579.
PMID: 32959888
PMC: 7707099.
DOI: 10.1111/bph.15268.
Fused 1,5-Naphthyridines: Synthetic Tools and Applications.
Masdeu C, Fuertes M, Martin-Encinas E, Selas A, Rubiales G, Palacios F
Molecules. 2020; 25(15).
PMID: 32752070
PMC: 7436086.
DOI: 10.3390/molecules25153508.
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.
Rottmann M, Jonat B, Gumpp C, Dhingra S, Giddins M, Yin X
Antimicrob Agents Chemother. 2020; 64(4).
PMID: 32041711
PMC: 7179297.
DOI: 10.1128/AAC.02181-19.
Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.
Lane T, Massey C, Comer J, Anantpadma M, Freundlich J, Davey R
PLoS Negl Trop Dis. 2019; 13(11):e0007890.
PMID: 31751347
PMC: 6894882.
DOI: 10.1371/journal.pntd.0007890.
The past, present and future of anti-malarial medicines.
Tse E, Korsik M, Todd M
Malar J. 2019; 18(1):93.
PMID: 30902052
PMC: 6431062.
DOI: 10.1186/s12936-019-2724-z.
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Pryce J, Hine P
Cochrane Database Syst Rev. 2019; 1:CD006404.
PMID: 30620055
PMC: 6353203.
DOI: 10.1002/14651858.CD006404.pub3.
Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.
Macintyre F, Ramachandruni H, Burrows J, Holm R, Thomas A, Mohrle J
Malar J. 2018; 17(1):402.
PMID: 30384848
PMC: 6211409.
DOI: 10.1186/s12936-018-2549-1.
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Blasco B, Leroy D, Fidock D
Nat Med. 2017; 23(8):917-928.
PMID: 28777791
PMC: 5747363.
DOI: 10.1038/nm.4381.
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.
Ekins S, De Siqueira-Neto J, McCall L, Sarker M, Yadav M, Ponder E
PLoS Negl Trop Dis. 2015; 9(6):e0003878.
PMID: 26114876
PMC: 4482694.
DOI: 10.1371/journal.pntd.0003878.
New insight-guided approaches to detect, cure, prevent and eliminate malaria.
Kumar S, Kumari R, Pandey R
Protoplasma. 2014; 252(3):717-53.
PMID: 25323622
DOI: 10.1007/s00709-014-0697-x.
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.
Bukirwa H, Unnikrishnan B, Kramer C, Sinclair D, Nair S, Tharyan P
Cochrane Database Syst Rev. 2014; (3):CD006404.
PMID: 24596021
PMC: 4448218.
DOI: 10.1002/14651858.CD006404.pub2.
Review of pyronaridine anti-malarial properties and product characteristics.
Croft S, Duparc S, Arbe-Barnes S, Craft J, Shin C, Fleckenstein L
Malar J. 2012; 11:270.
PMID: 22877082
PMC: 3483207.
DOI: 10.1186/1475-2875-11-270.
Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.
Supan C, Mombo-Ngoma G, Dal-Bianco M, Ospina Salazar C, Issifou S, Mazuir F
Antimicrob Agents Chemother. 2012; 56(6):3165-73.
PMID: 22430976
PMC: 3370764.
DOI: 10.1128/AAC.05359-11.